Poll: half favor DTC ban

Share this article:
Half of all Americans favor a ban on DTC advertising for new prescription drugs, according to a Harris Interactive survey sponsored by WSJ.com.
Asked if it was "a good idea to forbid direct-do-consumer advertising for new prescription drugs for some period of time" after approval, 51 percent of respondents to the online survey said yes and only 25 percent said no, with another 24 percent on the fence. Those numbers were virtually unchanged among people who take prescription drugs on a regular basis, but among adults 65 and older, a ban was slightly more popular, with 55 percent saying they favored a ban and only 19 percent opposing.
Asked what type of ban they favored, 35 percent favored a mandatory ban for all new drugs approved "for some limited period of time," while 16 said they preferred a voluntary ban "so that each pharmaceutical company could decide when to begin advertising to consumers." Only 23 percent would oppose any ban, and 25 percent were unsure.
Underlying the findings is a lack of trust among Americans regarding the FDA's ability to ensure complete and accurate risk-benefit information in DTC ads. Thirty-five percent said the agency does an excellent or good job, 61 percent a fair or poor job.
Last month as part of a new company code on DTC communications, Bristol-Myers Squibb announced a voluntary, 12-month moratorium on branded TV, radio and print ads for new drugs. The code also calls for simplified, easy-to-understand risk/benefit language in product communications. Excluded from the policy are more targeted forms of consumer communications such as disease awareness advertising and CRM.
Senate Majority Leader Bill Frist (R-Tenn.) has called for a two-year prohibition on DTC advertising for new drugs.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...